

An overview and management of osteoporosis

Tümay Sözen¹, Lale Özışık², Nursel Çalık Başaran²

Abstract

Osteoporosis -related to various factors including menopause and aging- is the most common chronic metabolic bone disease, which is characterized by increased bone fragility. Although it is seen in all age groups, gender, and races, it is more common in Caucasians (white race), older people, and women. With an aging population and longer life span, osteoporosis is increasingly becoming a global epidemic. Currently, it has been estimated that more than 200 million people are suffering from osteoporosis. According to recent statistics from the International Osteoporosis Foundation, worldwide, 1 in 3 women over the age of 50 years and 1 in 5 men will experience osteoporotic fractures in their lifetime. Every fracture is a sign of another impending one. Osteoporosis has no clinical manifestations until there is a fracture. Fractures cause important morbidity; in men, in particular, they can cause mortality. Moreover, osteoporosis results in a decreased quality of life, increased disability-adjusted life span, and big financial burden to health insurance systems of countries that are responsible for the care of such patients. With an early diagnosis of this disease before fractures occur and by assessing the bone mineral density and with early treatment, osteoporosis can be prevented. Therefore, increasing awareness among doctors, which, in turn, facilitates increase awareness of the normal populace, will be effective in preventing this epidemic.

Keywords: Osteoporosis, osteoporosis management, bone mineral density, fracture risk

Introduction

Osteoporosis is a disease that is characterized by low bone mass, deterioration of bone tissue, and disruption of bone microarchitecture: it can lead to compromised bone strength and an increase in the risk of fractures (1).

Osteoporosis is the most common bone disease in humans, representing a major public health problem. It is more common in Caucasians, women, and older people. Osteoporosis is a risk factor for fracture just as hypertension is for stroke. Osteoporosis affects an enormous number of people, of both sexes and all races, and its prevalence will increase as the population ages. It is a silent disease until fractures occur, which causes important secondary health problems and even death (Figure 1) (2).

It was estimated that the number of patients worldwide with osteoporotic hip fractures is more than 200 million (3). It was reported that in both Europe and the United States, 30% women are osteoporotic, and it was estimated that 40% post-menopausal women and 30% men will experience an osteoporotic fracture in the rest of their lives (4-6).

Osteoporosis is also an important health issue in Turkey, because the number of older people is increasing. The incidence rate for hip fracture increases exponentially with age in all countries as well as in Turkey, which is evident in the FRACTURK study (7). It was estimated that around the age of 50 years, the probability of having a hip fracture in the remaining lifetime was 3.5% in men and 14.6% in women (7).

Bone tissue is continuously lost by resorption and rebuilt by formation; bone loss occurs if the resorption rate is more than the formation rate. The bone mass is modeled (grows and takes its final shape) from birth to adulthood: bone mass reaches its peak (referred to as peak bone mass (PBM)) at puberty; subsequently, the loss of bone mass starts. PBM is largely determined by genetic factors, health during growth, nutrition, endocrine status, gender, and physical activity. Bone remodeling, which involves the removal of older bone to replace with new bone, is used to repair microfractures and prevent them from becoming macrofractures, thereby assisting in maintaining a healthy skeleton. Menopause and advancing age cause an imbalance between resorption and formation rates (resorption becomes higher than absorption), thereby increasing the risk of fracture. Certain factors that increase resorption more than formation also induce bone loss, revealing the microarchitecture. Individual trabecular plates of bone are lost, leaving an architecturally weakened structure with significantly reduced mass; this leads to an increased risk of fracture that is aggravated by other aging-associated declines in functioning. Increasing evidence suggests that rapid



1 Department of Internal Medicine,
Near East University School of
Medicine, Nicosia, Turkish Republic of
Northern Cyprus

2 Department of Internal Medicine,
Hacettepe University School of
Medicine, Ankara, Turkey

Address for Correspondence:
Lale Özışık, Department of Internal
Medicine, Hacettepe University
School of Medicine, Ankara, Turkey

E-mail: lalezoz@gmail.com

Submitted: 07.06.2016

Accepted: 08.08.2016

Available Online Date: 30.12.2016

Copyright 2017 © Medical Research and
Education Association




Figure 1. Comparative incidences of osteoporosis-related fractures, new strokes, heart attacks, and invasive breast cancer in women in the United States (6)

bone remodeling (as measured by biochemical markers of bone resorption or formation) increases bone fragility and risk of fracture.

There are factors associated with an increased risk of osteoporosis-related fractures. These include general factors that relate to aging and sex steroid deficiency, as well as specific risk factors such as use of glucocorticoids (which cause decreased bone formation and bone loss), reduced bone quality, and disruption of microarchitectural integrity. Fractures result when weakened bone is overloaded, often by falls or certain daily chores (8).

Classification

Osteoporosis can be classified into two main groups by considering the factors affecting

Table 1. Secondary causes of osteoporosis (2, 6)

Lifestyle changes	Genetic diseases	Endocrine disorders	Other
Vitamin D insufficiency	Cystic fibrosis	Central obesity	AIDS/HIV
High salt intake	Glycogen storage diseases	Cushing's syndrome	Amyloidosis
Smoking (active or passive)	Menkes steely hair syndrome	Diabetes mellitus (types 1 and 2)	Chronic obstructive lung disease
Alcohol abuse	Osteogenesis imperfecta	Hyperparathyroidism	Congestive heart failure
Immobilization	Riley–Day syndrome	Thyrotoxicosis	Chronic metabolic acidosis
Excessive thinness	Ehler Danlos	Hypogonadal states:	Depression
Frequent falling	Hemochromatosis	Androgen insensitivity	End-stage renal disease
Low calcium intake	Marfan syndrome	Athletic amenorrhea	Hypercalciuria
Inadequate physical activity	Parental history of hip fracture	Premature menopause (<40 years)	Post-transplant bone disease
Excess vitamin A	Gaucher's disease	Hyperprolactinemia	Idiopathic scoliosis
	Homocystinuria	Panhypopituitarism	Sarcoidosis
	Hypophosphatasia	Anorexia nervosa	Weight loss
	Porphyria	Turner's and Klinefelter's syndromes	
Gastrointestinal disorders	Hematological disorders	Neurological and musculoskeletal factors	Rheumatologic and autoimmune diseases
Celiac disease	Hemophilia	Epilepsy	Ankylosing spondylitis
Gastric bypass	Leukemia and lymphomas	Multiple sclerosis	Systemic lupus
Gastrointestinal surgery	Sickle cell disease	Muscular dystrophy	Rheumatoid arthritis
Malabsorption	Multiple myeloma	Parkinson's disease	Systemic lupus
Inflammatory bowel disease	Monoclonal gammopathies	Spinal cord injury	Other rheumatic and autoimmune diseases
Pancreatic disease	Systemic mastocytosis	Stroke	
Primary biliary cirrhosis	Thalassemia	Proximal myopathy	

Medications

Aluminum (in antacids), Anticoagulants (heparin), Anticonvulsants, Aromatase inhibitors, Barbiturates, Cancer chemotherapeutic drugs, Depo-medroxyprogesterone (premenopausal contraception), Glucocorticoids (≥5 mg/day prednisone or equivalent for ≥3 months), GnRH (gonadotropin-releasing hormone) agonists, Lithium Cyclosporine A, Tacrolimus, Methotrexate, Parental nutrition, Proton pump inhibitors Selective serotonin reuptake inhibitors, Tamoxifen® (premenopausal use) Thiazolidinediones, Thyroid hormones (in excess), warfarin
 AIDS/HIV: acquired immune deficiency syndrome/human immunodeficiency virus

bone metabolism:

- Primary osteoporosis
- Secondary osteoporosis (Table 1) (2)
- Primary osteoporosis can also be divided into two subgroups:

Involitional Osteoporosis Type I

It is also known as postmenopausal osteoporosis, caused by the deficiency of estrogen, mainly affecting the trabecular bone; therefore, women are more susceptible to osteoporosis than men, as evident by a men/women ratio of 4/5.7 (2).

Involitional Osteoporosis Type II

It is also called senile osteoporosis, and it is related to bone mass lost due to the aging of cortical and trabecular bones (2, 9).

- Secondary osteoporosis:

Different diseases, medications, and lifestyle changes can cause osteoporosis (Table 1).

Clinical Consequences

Clinical evaluation

Osteoporosis has been mislabeled as a women's disease by the public, but it affects men, too: young men are afflicted by it, which usually goes undiagnosed until a fracture brings the patient to a doctor. However, delayed interventions are usually unsuccessful. The diagnosis of osteoporosis is never taken as primary osteoporosis without ruling out the secondary causes. A good history and physical examination of the patient always reveal certain clues about the presence of another disease: certain special laboratory evaluations might be needed to rule out other responsible diseases.

Clinical findings and complications

Fractures and their complications are the relevant clinical sequelae of osteoporosis. Osteoporosis is a silent disease until the patient experiences a fracture. A recent fracture at any major skeletal site, such as vertebrae (spine), proximal femur (hip), distal forearm (wrist), or shoulder in an adult older than 50 years with or without trauma, should suggest that the diagnosis of osteoporosis needs further urgent assessment involving diagnosis and treatment. Clinical risk factors are listed in (Table 2). The pathogenesis of osteoporosis-related fractures is summarized in (Figure 2) (10, 11).

Fractures may cause chronic pain, disability, and death. Hip fractures are associated with 15–20% increased mortality rate within 1 year, with a higher mortality rate in men than in women, followed by a 2.5-fold increased risk




Figure 2. Pathogenesis of osteoporosis-related fractures (10, 11)

Table 2. Clinical risk factors used for the assessment of fracture probability (10)

Age

Sex

Low body mass index (≤ 19 kg/m²)

Previous fragility fracture, particularly of the hip, wrist and spine including morphometric vertebral fracture

Secondary causes of osteoporosis including:

Parental history of hip fracture

Current glucocorticoid treatment (any dose, by mouth for three months or more)

Current smoking Alcohol intake of three or more units daily

Rheumatoid arthritis

Untreated hypogonadism in men and women

Prolonged immobility

Organ transplantation

Type I diabetes

Hyperthyroidism

Gastrointestinal disease

Chronic liver disease

Chronic obstructive pulmonary disease

Frequent falling

of future fractures. Approximately 20–50% hip fracture patients require long-term nursing home care and suffer from decreased quality of life, social isolation, depression, and loss of self-esteem (12). Fractures that occur spontaneously or following minor trauma (e.g., fall from a standing height or less)—called fragility fractures—are very common in osteoporotic individuals (13).

Vertebral fractures might occur during daily chores without any trauma or fall, and they are the predictors of future fracture risk: the probability is fivefold for subsequent vertebral fractures and twofold to threefold for fractures at other sites (14, 15).

The first complaint of the patient might be the loss of height caused by vertebral compression

due to fractures, which is more evident in the presence of multiple fractures; this abnormality can be objectively detected by increased occiput-to-wall distance caused by dorsal kyphosis (dowager's hump). The determination of historical height loss (difference between the current height and peak height at an age of 20 years) of 1.5 inches (4 cm) or more and prospective height loss (difference between the current height and a previously documented height measurement) of 0.8 inches (2 cm) or more is important. Multiple vertebral thoracic fractures may result in restrictive lung disease and secondary heart problems. Lumbar fractures may decrease the volumes between the ribs to the pelvis, alter abdominal anatomy, crowd internal organs (particularly the gastrointestinal system, causing gastrointestinal complaints such as premature satiety, reduced appetite, abdominal pain, constipation, and distention); further, back pain (acute and chronic), prolonged disability, poor self-image, social isolation, depression, and positional restriction are other problems created by compression fractures in addition to increased mortality (16).

Dorsal kyphosis is also seen in some older people without fractures so it is not a diagnostic criterion for osteoporosis.

There are some other factors that increase fracture risk and osteoporosis, independent of bone mineral density (BMD) (17):

- Age of the patient (18)
- A low body mass index (BMI < 21 kg/m²) is a significant risk factor for hip fracture (19).
- A history of a previous osteoporotic fracture is another important factor for further fracture risk and almost doubles the risk of spinal fractures (15)
- Parental history of hip fracture (20)
- Smoking (21)
- Oral glucocorticoids ≥ 5 mg/d of prednisone for >3 months (ever) (22)
- There is a dose-dependent relationship between alcohol intake and fracture risk. Daily intake of 3 or more units of alcohol is associated with fracture risk (23)
- Rheumatoid arthritis increases fracture risk independently of BMD, as well as the use of glucocorticoids (24)
- Falls are an important risk factor for osteoporotic fractures

Environmental and medical factors increasing falls and measures that can be taken to prevent such falls at home are listed in (Table 3) (25).

Prevention of falls

Falls are the cause of a majority of osteoporotic fractures; therefore, a program needs to be

Table 3. Risk factors for falls and multifactorial interventions to prevent falls in community-dwelling older people (1, 6, 25)

Environmental risk factors	
Lack of assistive devices	Obstacles in the walking paths
Loose throw rugs	Slippery conditions
Low level lighting	
Medical risk factors	
Age	Arrhythmias
Anxiety and agitation	Depression
Poor vision	Orthostatic hypotension
Dehydration	Previous falls or fear of falling
Medications causing sedation (narcotic analgesics, anticonvulsants, psychotropics)	Reduced problem solving or mental acuity and diminished cognitive skills
Vitamin D insufficiency [serum 25-hydroxyvitamin D (25 (OH) D) <30 ng/mL (75 nmol/L)]	Urgent urinary incontinence
Malnutrition	
Neurological and musculoskeletal risk factors	
Kyphosis	Reduced proprioception
Impaired transfer and mobility	
Poor balance	Weak muscles/sarcopenia
Deconditioning	Diseases listed in Table 1
Multifactorial interventions to prevent of falls in community-dwelling elderly people	
Appropriate exercise program after evaluation of the multifactorial fall risk assessment	
Withdrawal or minimization of psychoactive medications (e.g., sedative hypnotics, anxiolytics, antidepressants) and antipsychotics	
Reduced visual acuity due to either cataracts, macular degeneration, glaucoma are very common in elderly and increases risk of falling, should be treated orderly	
Treatment of postural hypotension	
Treatment of cardiac problems especially arrhythmias	
Exercise, in the form of strength training and balance, gait, and coordination training, is effective in reducing falls	
Selective use of orthotics could help reduce discomfort, prevent falls and fractures, and improve quality of life	
Management of foot problems and footwear	
- Encourage patient to wear low-heeled shoes	
Adaptation or modification of home environment	
- Rugs should be anchored to prevent slipping	
- Minimize clutter	
- Remove loose wires	
- Use of nonslippery door mats	
- Install handrails in bathrooms, halls, and long stairways	
- Light entrances, hallways, halls, stairways	

Table 4. WHO definitions of osteoporosis based on BMD (26)

Classification	Bone Mineral Density	T Score
Normal	Within 1 SD of the mean level for a young adult reference population	T score at - 1.0 and above
Low bone mass (Osteopenia)	Between 1 and 2.5 SD below that of the mean level for a young adult reference population	T score between -1.0 and -2.5
Osteoporosis	2.5 or more below that of the mean level for a young adult reference population	T score at or below -2.5
Severe or established osteoporosis	2.5 or more below that of the mean level for a young adult reference population with fractures	T score at or below -2.5 with one or more fractures

WHO: World Health Organization; BMD: bone mineral density; SD: standard deviation

structured for the effective treatment of osteoporosis in order to prevent falls (Table 3). Older and frail persons and those who have had a stroke or are taking medications that decrease mental alertness are particularly predisposed toward falls. Although several interventions reduce the risk of falling, none of them apparently reduce the risk of fractures. Hip protectors do not reduce the risk of falling, but they reduce the risk of fracture. Patients at an older age with severe kyphosis, back discomfort, and gait instability could benefit from weight-bearing exercises, back strengthening, and balance training therapies.

Diagnosis of osteoporosis

Bone strength can be defined using BMD (70%) and bone quality (20%). It is easy to measure BMD, but, in clinical settings, bone quality is not measurable yet. The diagnosis of osteoporosis is established by the measurement of BMD or by the occurrence of a fragility fracture of the hip or vertebra or in the absence of major trauma (e.g., motor vehicle accident or fall from multiple stories). Laboratory testing revealed no secondary causes of osteoporosis (Table 1).

Bone mineral density is measured by means of dual X-ray absorptiometry (DXA); it is the actual expression of the bone in absolute terms of grams of mineral (primarily, as g/cm² of calcium) per square centimeter of the scanned bone. BMD measurements of the hip and spine are used to establish or confirm the diagnosis of osteoporosis to predict future fracture risk and monitor patients. The difference between the patient's BMD and mean BMD of young females aged in the range of 20-29 years (divided by the standard deviation (SD) of the reference population) yields the T-score; comparing the BMD of a particular age, sex, and ethnicity-matched adult reference population is called the Z-score. As defined by the World Health Organization (WHO), osteoporosis is present when BMD is 2.5 SD or more below the average value for young healthy women (a

T-score of <-2.5 SD). A second, higher threshold describes "low bone mass" or osteopenia as a T-score that lies between -1 and -2.5 SD. "Severe" or "established" osteoporosis denotes osteoporosis that has been defined in the presence of one or more documented fragility fractures (Table 4) (26).

Bone mineral density can be easily measured to detect bone density, but the degree of deterioration of the bone tissue cannot be measured in clinical settings, except for the biochemical markers of bone tissue (27).

Fracture risk is closely correlated with bone strength and increases exponentially as the BMD decreases. Dual energy X-ray absorptiometry (DXA) measurements of hips are the best predictors of hip fracture risks. The measurements of the total hip, femoral neck, or total lumbar spine (or a combination of these sites) are the preferred measurement sites. If the hip and/or lumbar spine sites cannot be measured or become unusable (e.g., hyperparathyroidism or very obese patients), one-third (33%) of the site radius can be used. Other hip regions, including Ward's area and the greater trochanter, should not be used for diagnosis. BMD may be measured at either hip.

T-score criteria are applied for the BMD measured by means of central DXA at the femoral hip and lumbar spine for postmenopausal women and men aged 50 years and older. For premenopausal women, men less than 50 years of age, and children, the BMD diagnostic classification as defined by the WHO should not be applied. The International Society for Clinical Densitometry (ISCD) recommends using ethnic- or race-adjusted Z-scores: Z-scores of -2.0 or lower are defined as "low bone mineral density for chronological age" or "below the expected range for age" and those above -2.0 are defined as "within the expected range for age" (28).

The United States Preventive Services Task Force (USPSTF) recommends the testing of all women

aged 65 years and above and younger women whose fracture risk is equal to or greater than that of a 65-year-old white woman who exhibits no additional risk factors (29). Indications for measuring BMD are listed at (Table 5) (13).

Fracture Risk Assessment Tool Model (FRAX)

The most important health consequence of osteoporosis is fractures. Recently, algorithms have been developed to predict the risk of fracture in individuals that incorporate significant predictors of fracture risk in addition to BMD. Estimating the 10-year risk of a major osteoporotic fracture (i.e., fracture of the hip, vertebra (clinical), forearm, or proximal humerus) is possible with algorithms that integrate the weight of clinical risk fractures for fracture risk with or without information on the BMD have been developed (www.shef.ac.uk/FRAX). They can be used to compute the 10-year probability of hip fracture or a major osteoporotic fracture (clinical spine, hip, forearm, or humerus).

Clinical risk factors used in FRAX are as follows (26):

- Current age
- Sex
- A prior osteoporotic fracture (including clinical and asymptomatic vertebral fractures)
- BMD of femur neck
- Low BMI (BMI < 21 kg/m²)
- Oral glucocorticoids ≥ 5 mg/d of prednisone for > 3 months (ever)
- Rheumatoid arthritis
- Parental history of hip fracture
- Secondary causes of osteoporosis: Type-1 DM, early menopause < 40 years, etc.
- Being a past or current smoker
- Alcohol intake (3 or more drinks/day)

Probabilities have been computed for several countries (30).

A vertebral fracture is consistent with the diagnosis of osteoporosis, even in the absence of a bone density diagnosis; it is an indication for pharmacologic treatment with osteoporosis

Table 5. Indications for measuring BMD (13)

Older adults (age >50 yr)	Younger adults (age <50 yr)
Age \geq 65 yr (both women and men)	Fragility fracture
Clinical risk factors for fracture (menopausal women, men aged 50-64 yr)	Hypogonadism or premature menopause (age <45 yr)
- Fragility fracture after the age of 40 yr	Malabsorption syndrome
- Prolonged use of glucocorticoids	Prolonged use of glucocorticoids*
- Use of other high-risk medications	Use of other high-risk medications**
- Vertebral fracture or osteopenia identified on radiography	Primary hyperparathyroidism
- Other disorders strongly associated with osteoporosis	Other disorders strongly associated with rapid bone loss and/or Fracture
- Current smoking	
- High alcohol intake	
- Vertebral fracture or osteopenia identified on radiography	
- Low body weight (<60 kg) or major weight loss (>10% of body weight at the age of 25 yr)	
- Rheumatoid arthritis	
- Parental hip fracture	

BMD: bone mineral density; yr: years; kg: kilogram

*At least 3 months cumulative therapy in the previous year at a prednisone-equivalent dose of 7.5 mg

**Aromatase inhibitors or androgen deprivation therapy use of thiazolidinediones, proton pump inhibitors

Table 6. Indications for vertebral imaging (2)

Indications for Vertebral Imaging

Women aged \geq 70 years or men aged \geq 80 years

Difference between the current height and peak height at age 20 (historical height loss) \geq 4 cm (>1.5 inches)

Self-reported but undocumented prior vertebral fracture

Prospective height loss (difference between the current height and a previously documented height measurement) of 2 cm (0.8 inches) or more

Recent or ongoing long-term glucocorticoid treatment (Glucocorticoid therapy equivalent to \geq 5 mg of prednisone or equivalent per day for \geq 3 months)

If bone density measurement is not available, vertebral imaging may be considered based on age alone

cm: Centimeter; mg: milligram

medication to reduce subsequent fracture risk. Unrecognized vertebral fractures may change the diagnostic classification, alter future fracture risk calculations, and affect treatment decisions. Regardless of BMD, age, and other clinical risk factors, radiographically confirmed vertebral fractures are a sign of impaired bone quality and strength and strong predictor of new vertebral and other fractures (15).

Vertebral imaging (Vertebral fracture assessment)

Asymptomatic vertebral fractures are very common in older patients necessitating vertebral imaging, which can be performed using a lateral thoracic and lumbar spine X-ray or lateral Vertebral Fracture Assessment (VFA) available on most DXA machines; this can be performed at the time of BMD assessment. Lateral spine imaging using conventional ra-

diography or densitometric VFA is indicated when the T-score $<$ -1.0 at the spine, total hip, femoral neck, and other sites is present (2) (Table 6).

Biochemical bone turnover marker (BTM)

Bone remodeling (or turnover) occurs throughout life to repair fatigue damage and microfractures in the bone and to maintain mineral homeostasis. Biochemical markers of bone remodeling include resorption markers, namely serum C-terminal telopeptide type-I collagen (s-CTX) and urinary N-telopeptide (NTX), and formation markers, such as serum procollagen type-I N-terminal propeptide (s-PINP), which may provide information on fracture risk independent of BMD and predict the rapidity of bone loss in untreated patients. Therefore, the fracture risk prediction might get enhanced by their inclusion in assessment algorithms. Further, they can be used to predict the response to treatments. It was shown that there is a significant relationship between the reduction in BTMs following antiresorptive therapy and reduction in vertebral and non-vertebral fracture risk. In general, these studies showed that the greater the decrease in BTM, larger is the reduction in fracture risk.

International Osteoporosis Foundation (IOF) and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Working Group evaluated BTMs in the prediction of fracture risk and for monitoring treatment; it was recommended that bone formation markers (s-PINP) and bone resorption markers (s-CTX) should be used as reference markers and measured by standardized assays in observational and intervention studies (31).

Following studies are necessary to rule out secondary osteoporosis (32):

Complete blood count (CBC)

Serum creatinine, calcium, phosphorus, and magnesium

Alanin aminotransferase (ALT), aspartat aminotransferase (AST), and alkaline phosphatase (AP)

Thyroid-stimulating hormone (TSH) and free T4

Vitamin D (V-D) (25 (OH) D)

Parathyroid hormone (PTH)

Total testosterone and gonadotropin in younger men

BTMs

Considered in select patients

Serum protein electrophoresis (SPEP), serum immunofixation, and serum-free light chains

Tissue transglutaminase antibodies (IgA and IgG)

Iron and ferritin levels

Homocysteine

Prolactin

Tryptase

24-h urinary calcium

Urinary protein electrophoresis (UPEP)

Urinary-free cortisol level

Urinary histamine

Approach to a patient with osteoporosis

A detailed history and physical examination together with BMD assessment, vertebral imaging to diagnose vertebral fractures (when appropriate), and the WHO-defined 10-year estimated fracture probability test are utilized to establish an individual patient's fracture risk (30).

All postmenopausal women and men aged 50 years and above should be evaluated for osteoporosis risk in order to determine the need for BMD testing and/or vertebral imaging. In general, the more the risk factors, larger is the risk of fracture. Osteoporosis is preventable and treatable, but because there are no warning signs prior to a fracture, many people are not being diagnosed in time to receive effective therapy during the early phase of this disease. The factors that increase the risk of osteoporosis-related fractures are listed in (Table 2).

Universal recommendations for all patients

Several interventions, including an adequate intake of calcium and V-D, are fundamental aspects for any osteoporosis prevention or treatment program, including lifelong regular weight-bearing and muscle-strengthening exercises, cessation of tobacco use and excess alcohol intake, and treatment of risk factors for falling (Table 2, 3).

In order to maintain serum calcium at a constant level, an external supply of adequate calcium is necessary; otherwise, low serum calcium levels promote bone resorption to bring the calcium levels to normal. Calcium requirements increase among older persons; thus, the older population is particularly susceptible to

calcium deficiency. The Institute of Medicine (IOM) recommends a daily intake of 1000 mg/day for men aged 50–70 years and 1200 mg of calcium for women aged over 50 years and men aged over 70 years (33, 34).

All calcium preparations are better absorbed when taken with food, particularly in the absence of the secretion of gastric acid. For optimal absorption, the amount of calcium should not exceed 500–600 mg per dose. Calcium carbonate is the least expensive and necessitates the use of the fewest number of tablets, but it may cause gastrointestinal (GI) complaints. Calcium citrate is more expensive, and a larger number of tablets are needed to achieve the desired dose; however, its absorption is not dependent on gastric acid and it does not cause GI complaints. Some food products contain excess oxalate, which prevents absorption of calcium by binding with it. Intakes in excess of 1200–1500 mg/day may increase the risk of developing kidney stones, cardiovascular diseases, and strokes.

Vitamin D is necessary for calcium absorption, bone health, muscle performance, and balance. The IOM recommends a dose of 600 IU/day until the age of 70 years in adults and 800 IU/day thereafter (34–36). Chief dietary sources of V-D include V-D-fortified milk, juices and cereals, saltwater fish, and liver. Supplementation with V-D₂ (ergocalciferol) or V-D₃ (cholecalciferol) may be used.

Many older patients are at a high risk for V-D deficiency, which include the following: patients with malabsorption issues (e.g., celiac disease) or other intestinal diseases (e.g., inflammatory bowel disease, gastric bypass surgery); gastric acidity; pernicious anemia; proton pump inhibitors; chronic renal or liver insufficiency; patients on medications that increase the breakdown of V-D (e.g., some anticonvulsive drugs); or glucocorticoids, which decrease calcium absorption; housebound and chronically ill patients; persons with limited sun exposure; individuals with very dark skin; and obese individuals.

Serum 25 (OH) D levels should be measured in patients at the risk of V-D deficiency. V-D supplements should be recommended in amounts sufficient to bring the serum 25 (OH) D level to approximately 30 ng/mL (75 nmol/L). Many patients with osteoporosis will need more than the general recommendation of 800–1000 IU/day. The safe upper limit for V-D intake for the general adult population was increased to 4000 IU/day in 2010.

Alcohol: Excessive intake of alcohol has detrimental effects on bones, so it should be avoided.

The mechanisms are multifactorial and include predisposition to falls, calcium deficiency, and chronic liver disease, which, in turn, results in predisposition toward V-D deficiency. Persons predisposed toward osteoporosis should be advised against consuming more than 7 drinks/week, 1 drink being equivalent to 120 mL of wine, 30 mL of liquor, or 260 mL of beer (23).

Caffeine: Patients should be advised to limit their caffeine intake to less than 1 to 2 servings (8 to 12 ounces in each serving) of caffeinated drinks per day. Some studies showed that there is a relationship between caffeine consumption and fracture risk (37).

Exercise: A regular weight-bearing exercise regimen (for example, walking 30–40 min per session) along with back and posture exercises for a few minutes on most days of the week should be advocated throughout life. Children and young adults who are active reach a higher peak bone mass than those who are not (38).

Among older patients, these exercises help slow bone loss attributable to disuse, improve balance, and increase muscle strength, ultimately reducing the risk of falls (39). Patients should avoid forward flexion, side-bending exercises, or lifting heavy objects because pushing, pulling, lifting, and bending activities compress the spine, leading to fractures.

Prevention of falls: Falls are the precipitating cause for most osteoporotic fractures; some measures should be taken to prevent falls in the household, particularly for patients who are frail, taking some medications that affect mental alertness, thereby resulting in a stroke (40) (Table 3).

Pharmacologic therapy

All osteoporotic patients should be evaluated for secondary causes of osteoporosis before starting treatment and subjected to BMD measurements using central DXA, including vertebral imaging studies when appropriate: the BTM levels should be obtained if monitoring of the treatment is planned.

Who should be considered for treatment?

Postmenopausal women and men aged 50 years and above who present with the following should be considered for treatment:

- A hip or vertebral fracture (clinically apparent or found on vertebral imaging) because it was shown that the patients with spine and hip fractures had reduced fracture risk with pharmacologic therapy, irrespective of the T score.

Table 7. Drugs used for prevention and treatment of osteoporosis

Medication	Postmenopausal osteoporosis		Glucocorticoid induced osteoporosis		In Men
	Prevention	Treatment	Prevention	Treatment	Treatment
Estrogen	Multiple regimens				
Denosumab		60 mg sc/6mo			
Raloxifene	60mg po/d	60 mg po/d			
Ibandronate	2.5 mg po/d	2.5 mg po/d			
	150 mg/mo	150 mg po/mo			
		3 mg iv/3mo			
Alendronate 5-10-70 mg	5 mg po/d	10 mg po/d		5 mg po/d	10 mg po/d
	35 mg po/wk	70 mg po/wk		10mg po/d	70 mg po/wk
		70mg po+VD			
Risedronate 5-35-75 mg	5 mg po/d	5 mg po/d	5 mg po/d	5 mg po /d	35 mg po/wk
		35 mg po/wk			150 mg po/mo
		150 mg/po/mo			
Strontium Ranelate 2gr po, eff	2 gr/d		2 gr/d	2 gr/d	
Zoledronic acid	5mg iv/2 yr	5 mg iv/yr	5 mg iv/yr	5 mg iv/yr	5 mg iv/yr
Teriparatid		20 ug sc/d		20 ug sc/yr	20 ug sc/d

iv:intravenous; po: oral; sc: subcutaneous; eff: effervescent yr: year; wk: week; mo: month; d: day

Table 8. Drugs that decreases the risk of fractures

Drug	Vertebral	Nonvertebral	Hip
Alendronate	Yes	Yes	Yes
Risedronate	Yes	Yes	Yes
Zoledronic Acid	Yes	Yes	Yes
Denosumab	Yes	Yes	Yes
Teriparatid demonstrated	Yes	Yes	No effect
Ibandronat demonstrated	Yes	Yes	No effect
Raloxifene demonstrated	Yes	Yes	No effect

- Determination of fractures when the T-score ≤ -2.5 at the femoral neck, total hip, or lumbar spine
- Low bone mass (T-score between -1.0 and -2.5 at the femoral neck or lumbar spine) and
- 10-year probability of a hip fracture $\geq 3\%$ or a 10-year probability of a major osteoporosis-related fracture $\geq 20\%$

The anti-fracture benefits of Food and Drug Administration (FDA)-approved drugs have mostly been studied in women with postmenopausal osteoporosis. There are limited fracture data for men and cases involving glucocorticoid-induced osteoporosis.

Pharmacologic agents for treatment of osteoporosis

The main goals of therapy in osteoporotic patients are as follows:

- To prevent fractures by improving bone strength and reducing the risk of falling and injury
- To relieve symptoms of fractures and skeletal deformity
- To maintain normal physical function

Most of the current therapies in the prevention of osteoporosis and fractures are designed to decrease bone resorption and they are known as antiresorptive agents. They include estrogen; bisphosphonates (BPs) such as alendro-

nate, risedronate, ibandronate, and zoledronic acid; selective estrogen receptor modulators (SERM) raloxifene; human monoclonal antibody against receptor activator of NF- κ B ligand (RANKL) denosumab; and strontium ranelate (SR). The agents used for the prevention or treatment of osteoporosis and drugs that decrease the risk of fractures are shown in (Table 7, 8) respectively.

All antiresorptive agents increase bone mass, but only alendronate, risedronate, zoledronic acid, and SR are shown to decrease both vertebral and hip fractures. However, the efficacy of the remaining is only for vertebral fractures. Nonetheless, hip fractures cause increased morbidity, mortality, and healthcare costs as compared to vertebral fractures. All of these antiresorptive therapies do not stimulate bone formation, except currently available anabolic agents (namely, PTH), which increase bone strength and bone formation. They are particularly helpful for those having severe or established osteoporosis. Unfortunately, the adherence to and persistence toward these techniques are poor toward all osteoporosis therapies, which decrease the success of treatment.

Antiresorptive agents

Bisphosphonates are the most widely used drugs for the treatment of osteoporosis.

Alendronate is used in the prevention and treatment of postmenopausal, glucocorticoid-induced, and male osteoporosis cases. Trials lasting up to 10 years have been reported for postmenopausal osteoporosis (41). Efficacy and safety beyond 10 years have not yet been established. A drug holiday of 1 or 2 years is suggested after 4-5 years of therapy (and longer for those with severe osteoporosis).

Risedronate is used in men and women for the prevention and treatment of osteoporosis and glucocorticoid-induced osteoporosis. A drug holiday of up to 1 year after 7 years of therapy has been suggested (42).

Ibandronate is another BP used for the prevention and treatment of postmenopausal osteoporosis, which has proven efficacy in reducing the risk of spinal fractures of postmenopausal women suffering from osteoporosis, but it is not proven in reducing non-vertebral or hip fractures except for higher-risk subgroup. Ibandronate has been studied in trials of up to 3 years and its efficacy and safety beyond 3 years is not known (43).

Zoledronic acid is used for the prevention and treatment of postmenopausal osteoporosis and osteoporosis in men as well as glucocorticoid-induced osteoporosis. It is given once yearly, administered intravenously, as a 5-mg infusion over a minimum of 15 min (44).

Cautions to be taken, contraindications, and complications to BP therapy

The absorption of oral BPs is less than 1% with any food, beverage other than plain water, or medications within 2 h after drug administration. Oral BPs should be used with caution: they should not be used in patients with active upper GI diseases, inability to remain upright for 30-60 min, anatomic or functional esophageal abnormalities that might delay the transit of the tablet (achalasia, stricture, etc.), V-D deficiency, hypocalcemia, and hypersensitivity to drug and kidney failure (should be used with caution when the glomerular filtration rate is below 30 ml/min for risedronate and ibandronate or below 35 mL/min for alendronate and zoledronate). Intravenous administration of BPs, such as ibandronate and zoledronate, causes acute phase reactions (e.g., fever, muscle aches, etc.) with the first dose and it can last several days in some patients; this can be prevented by administering acetaminophen. BPs have been reported to cause bone, joint, or muscle complaints; osteonecrosis of the jaw (ONJ); and alendronate causing atypical fractures (45).

Raloxifene has been shown to reduce the risk of fractures of the spine in women with postmenopausal osteoporosis, but its efficacy in reducing non-vertebral or hip fractures has not been demonstrated. Increases in hot flashes are contraindicated in fertile women and those who have had venous thromboembolic disease (46).

Estrogen replacement therapy (ERT) is used for the prevention of postmenopausal osteoporosis for those showing a significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate, but estrogen has never been approved for the treatment of osteoporosis.

Strontium ranelate reduces vertebral and non-vertebral fracture risk in postmenopausal osteoporotic women, irrespective of age or severity of the underlying disease (47, 48). It was demonstrated that SR increases BMD and reduces fracture risk in postmenopausal women and in men with osteoporosis. Although SR has not been approved by the FDA, it was approved by the European Medicines Agency (EMA) in the treatment of osteoporosis in men with an increased risk of fracture.

Denosumab (human monoclonal antibody against RANKL) is used in the treatment of postmenopausal women at a high risk of fracture, patients having a history of osteoporotic fractures, or patients who have failed or are intolerant to other available osteoporosis therapies. It has been shown to reduce the risk of fractures of the spine, hip, and non-vertebral sites. Hypocalcemia must be corrected before the initiation of therapy. Serious infections, dermatitis, rashes, and eczema may occur. ONJ has been reported; drug discontinuation is suggested with severe symptoms. Efficacy and safety beyond 6 years with denosumab have not yet been established (49).

Teriparatide (recombinant human PTH 1-34) is used in the treatment of postmenopausal osteoporosis with a high risk of fracture, those who have failed or are intolerant to previous osteoporosis therapies, and to increase bone mass in men with idiopathic or hypogonadal osteoporosis. Teriparatide is also approved for the treatment of men and women with glucocorticoid-induced osteoporosis. Serum calcium, PTH, and 25 (OH) D levels should be checked before treatment (50). Teriparatide has a "black box" warning because of the occurrence of osteosarcomas in rats treated with very high doses of teriparatide; it is contraindicated in patients at increased risk of osteosar-

coma (those with Paget's disease of the bone), having open epiphyses, history of irradiation involving the skeleton, unexplained elevation of alkaline phosphatase levels of skeletal origin, or patients with primary or any other form of secondary untreated or unresolved hyperparathyroidism.

The drugs decreasing the fracture risk in vertebral and non-vertebral sites are listed in (Table 8).

Combination or sequential therapies

There is no evidence showing that a combination treatment with 2 or more osteoporosis drugs or sequential use of therapeutically agents shows any benefit on the natural history of osteoporosis or fracture risk reduction. In most patients, long-term treatment needs to be continued. The beneficial effects of treatment with drugs other than BPs wear off soon after the therapy is discontinued, but they may be maintained for longer periods of time after the cessation of BP therapy.

It is recommended that treatment review should be performed after 5 years for alendronate, risedronate, or ibandronate and after 3 years for zoledronic acid. Individuals with fracture risk should continue osteoporosis therapy without a drug holiday until we have convincing new data on the subject.

Conclusion

Osteoporosis is a common and silent disease until it is complicated by fractures that become common. It was estimated that 50% women and 20% of men over the age of 50 years will have an osteoporosis-related fracture in their remaining life. These fractures are responsible for lasting disability, impaired quality of life, and increased mortality, with enormous medical and heavy personnel burden on both the patient's and nation's economy. Osteoporosis can be diagnosed and prevented with effective treatments, before fractures occur. Therefore, the prevention, detection, and treatment of osteoporosis should be a mandate of primary healthcare providers.

Ethics Committee Approval: N/A.

Informed Consent: N/A.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept - T.S., L.O., N.C.B.; Design - T.S., L.O.; Supervision - T.S., L.O.; Resources - T.S., L.O.; Materials - T.S., L.O.; Data Collection and/or Processing - T.S., N.C.B.; Analysis and/or Interpretation - T.S., N.C.B.; Literature Search - T.S., N.C.B., L.O.; Writing Manuscript - T.S., L.O., N.C.B.; Critical Review - T.S., L.O., N.C.B.; Other - T.S., L.O., N.C.B.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study has received no financial support.

References

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. *JAMA* 2001; 285: 785-95.
2. Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, et al. Clinician's guide to prevention and treatment of osteoporosis. *Osteoporos Int* 2014; 25: 2359-81. [\[CrossRef\]](#)
3. Cooper C, Campion G, Melton LJ 3rd. Hip fractures in the elderly: a world-wide projection. *Osteoporos Int* 1992; 2: 285-9. [\[CrossRef\]](#)
4. Reginster JY, Burlet N. Osteoporosis: a still increasing prevalence. *Bone* 2006; 38 (Suppl 1): S4-9. [\[CrossRef\]](#)
5. Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. *J Bone Miner Res* 2014; 29: 2520-6. [\[CrossRef\]](#)
6. Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. *Endocr Pract* 2010; 16 (Suppl 3): 1-37. [\[CrossRef\]](#)
7. Tuzun S, Eskiyurt N, Akarimyak U, Saridogan M, Senocak M, Johansson H, et al. Incidence of hip fracture and prevalence of osteoporosis in Turkey: the FRACTURK study. *Osteoporos Int* 2012; 23: 949-55. [\[CrossRef\]](#)
8. Riggs BL, Wahner HW, Seeman E, Offord KP, Dunn WL, Mazess RB, et al. Changes in bone mineral density of the proximal femur and spine with aging. Differences between the postmenopausal and senile osteoporosis syndromes. *J Clin Invest* 1982; 70: 716-23. [\[CrossRef\]](#)
9. Hannan MT, Felson DT, Dawson-Hughes B, Tucker KL, Cupples LA, Wilson PW, et al. Risk factors for longitudinal bone loss in elderly men and women: the Framingham Osteoporosis Study. *J Bone Miner Res* 2000; 15: 710-20. [\[CrossRef\]](#)
10. Compston J, Bowring C, Cooper A, Cooper C, Davies C, Francis R, et al. Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. *Maturitas* 2013; 75: 392-6. [\[CrossRef\]](#)
11. Cooper C, Melton LJ 3rd. Epidemiology of osteoporosis. *Trends Endocrinol Metab* 1992; 3: 224-9. [\[CrossRef\]](#)
12. Melton LJ 3rd, Achenbach SJ, Atkinson EJ, Thernau TM, Amin S. Long-term mortality following fractures at different skeletal sites: a population-based cohort study. *Osteoporos Int* 2013; 24: 1689-96. [\[CrossRef\]](#)
13. Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. *CMAJ* 2010; 182: 1864-73. [\[CrossRef\]](#)
14. Ensrud KE, Ewing SK, Taylor BC, Fink HA, Stone KL, Cauley JA, et al. Frailty and risk of falls, fracture, and mortality in older women: the study of osteoporotic fractures. *J Gerontol A Biol Sci Med Sci* 2007; 62: 744-51. [\[CrossRef\]](#)
15. Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, et al. A meta-analysis of previous fracture and subsequent fracture risk. *Bone* 2004; 35: 375-82. [\[CrossRef\]](#)
16. Siminowski K, Warshawski RS, Jen H, Lee K. The accuracy of historical height loss for the detection of vertebral fractures in postmenopausal women. *Osteoporos Int* 2006; 17: 290-6. [\[CrossRef\]](#)
17. Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. *Osteoporos Int* 2007; 18: 1033-46. [\[CrossRef\]](#)
18. D'Amelio P, Isaia GC. Male Osteoporosis in the Elderly. *Int J Endocrinol* 2015; 2015: 907689. [\[CrossRef\]](#)
19. De Laet C, Kanis JA, Oden A, Johansson H, Johnell O, Delmas P, et al. Body mass index as a predictor of fracture risk: a meta-analysis. *Osteoporos Int* 2005; 16: 1330-8. [\[CrossRef\]](#)
20. Fox KM, Cummings SR, Powell-Threets K, Stone K. Family history and risk of osteoporotic fracture. Study of Osteoporotic Fractures Research Group. *Osteoporos Int* 1998; 8: 557-62. [\[CrossRef\]](#)
21. Kanis JA, Johnell O, Oden A, Johansson H, De Laet C, Eisman JA, et al. Smoking and fracture risk: a meta-analysis. *Osteoporos Int* 2005; 16: 155-62. [\[CrossRef\]](#)
22. Kanis JA, Stevenson M, McCloskey EV, Davis S, Lloyd-Jones M. Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. *Health Technol Assess* 2007; 11: 1-231. [\[CrossRef\]](#)
23. Kanis JA, Johansson H, Johnell O, Oden A, De Laet C, Eisman JA, et al. Alcohol intake as a risk factor for fracture. *Osteoporos Int* 2005; 16: 737-42. [\[CrossRef\]](#)
24. Sarkis KS, Salvador MB, Pinheiro MM, Silva RG, Zerbini CA, Martini LA. Association between osteoporosis and rheumatoid arthritis in women: a cross-sectional study. *Sao Paulo Med J* 2009; 127: 216-22. [\[CrossRef\]](#)
25. Panel on Prevention of Falls in Older Persons, American Geriatrics Society and British Geriatrics Society. Summary of the Updated American Geriatrics Society/British Geriatrics Society clinical practice guideline for prevention of falls in older persons. *J Am Geriatr Soc* 2011; 59: 148-57. [\[CrossRef\]](#)
26. Kanis JA on behalf of the World Health Organization Scientific Group (2007) Assessment of osteoporosis at the primary health-care level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK. 2007.
27. Seeman E, Delmas PD. Bone quality—the material and structural basis of bone strength and fragility. *N Engl J Med* 2006; 354: 2250-61. [\[CrossRef\]](#)
28. Schousboe JT SJ, Bilezikian JP, Baim S. Executive Summary of the 2013 ISCD Position Development Conference on Bone Densitometry. *J Clin Densitom* 2013; 16: 455-66. [\[CrossRef\]](#)
29. Nelson HD, Haney EM, Chou R, Dana T, Fu R, Bougatsos C. Screening for osteoporosis: systematic review to update the 2002 U.S. Preventive Services Task Force Recommendation. Evidence Synthesis No. 77. AHRQ Publication No. 10-05145-EF-1. Rockville, Maryland: Agency for Healthcare Research and Quality, July 2010.
30. Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A. Case finding for the management of osteoporosis with FRAX—assessment and intervention thresholds for the UK. *Osteoporos Int* 2008; 19: 1395-408. [\[CrossRef\]](#)
31. Vasikaran S, Eastell R, Bruyere O, Foldes AJ, Garner P, Griesmacher A, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. *Osteoporos Int* 2011; 22: 391-420. [\[CrossRef\]](#)
32. Tannenbaum C, Clark J, Schwartzman K, Wallenstein S, Lapinski R, Meier D, et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. *J Clin Endocrinol Metab* 2002; 87: 4431-7. [\[CrossRef\]](#)
33. Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium; Ross AC, Taylor CL, Yaktine AL, et al, editors. Dietary Reference Intakes for Calcium and Vitamin D. Washington (DC): National Academies Press (US); 2011. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK56070/> doi: 10.17226/13050. [\[CrossRef\]](#)
34. Moyer VA. Vitamin D and calcium supplementation to prevent fractures in adults: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med* 2013; 158: 691-6. [\[CrossRef\]](#)
35. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. *JAMA* 2005; 293: 2257-64. [\[CrossRef\]](#)
36. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, Staehelin HB, Bazemore MG, Zee RY, et al. Effect of Vitamin D on falls: a meta-analysis. *JAMA* 2004; 291: 1999-2006. [\[CrossRef\]](#)
37. Hallström H, Wolk A, Glynn A, Michaëlsson K. Coffee, tea and caffeine consumption in relation to osteoporotic fracture risk in a cohort of Swedish women. *Osteoporos Int* 2006; 17: 1055-64. [\[CrossRef\]](#)
38. Rizzoli R, Bianchi ML, Garabédian M, McKay HA, Moreno LA. Maximizing bone mineral mass gain during growth for the prevention of fractures in the adolescents and the elderly. *Bone* 2010; 46: 294-305. [\[CrossRef\]](#)
39. Kelley GA, Kelley KS, Tran ZV. Exercise and lumbar spine bone mineral density in postmenopausal women: a meta-analysis of individual patient data. *J Gerontol A Biol Sci Med Sci* 2002; 57: M599-604. [\[CrossRef\]](#)
40. Robertson MC, Campbell AJ, Gardner MM, Devlin N. Preventing injuries in older people by preventing falls: a meta-analysis of individu-

- al-level data. *J Am Geriatr Soc* 2002; 50: 905-11. [\[CrossRef\]](#)
41. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. *N Engl J Med* 2004; 350: 1189-99. [\[CrossRef\]](#)
 42. Eastell R, Devogelaer JP, Peel NF, Chines AA, Bax DE, Sacco-Gibson N, et al. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. *Osteoporos Int* 2000; 11: 331-7. [\[CrossRef\]](#)
 43. Chesnut CH 3rd, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. *J Bone Miner Res* 2004; 19: 1241-9. [\[CrossRef\]](#)
 44. Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (Horizon): a multicentre, double-blind, double-dummy, randomised controlled trial. *Lancet* 2009; 373: 1253-63. [\[CrossRef\]](#)
 45. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. *J Bone Miner Res* 2010; 25: 2267-94. [\[CrossRef\]](#)
 46. Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, et al. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (Core) study. *J Bone Miner Res* 2005; 20: 1514-24. [\[CrossRef\]](#)
 47. Seeman E. Strontium ranelate: vertebral and non-vertebral fracture risk reduction. *Curr Opin Rheumatol* 2006; 18 (Suppl 1): S17-20. [\[CrossRef\]](#)
 48. Committee for Medicinal Products for Human Use. Summary of opinion (post authorisation): treatment of osteoporosis in men at increased risk of fracture. European Medicines Agency Website. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/000560/WC500127765.pdf. Published May 24, 2012. Accessed June 12, 2012. - See more at: <http://press.endocrine.org/doi/full/10.1210/jc.2012-3048#sthash.M7MrgBEV.dpuf>.
 49. Bone HG, Chapurlat R, Brandi ML, Brown JP, Czerwinski E, Krieg MA, et al. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the freedom extension. *J Clin Endocrinol Metab* 2013; 98: 4483-92. [\[CrossRef\]](#)
 50. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. *N Engl J Med* 2001; 344: 1434-41. [\[CrossRef\]](#)